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Stllnmary 
Experimental allergic encephalomyelitis (EAE) is a prototype for CD4 + T cell-mediated auto- 
immune diseases. Immunization with myelin basic protein (MBP) in B10.PL mice results in EAE, 
and a majority of animals recover  permanently from the disease. Most MBP-reactive  encephalitogenic 
T  cells recognize an immunodominant NH2-terminal  peptide,  Acl-9, and predominantly use 
the T cell receptor (TCR) V138.2 gene segment. Here we report that in mice recovering from 
MBP-induced EAE, peripheral T cells proliferate in response to a single immunodominant TCR 
peptide from the Vf38.2 chain (amino acids 76-101), indicating natural priming during the course 
of the disease. Cloned T cells, specific  for this TCR peptide, specifically  downregulate proliferative 
responses to Acl-9 in vivo and also protect mice from MBP-induced  EAE. These regulatory 
T cells express CD4 molecules and recognize a dominant peptide from the TCR variable  framework 
region of VBS.2, in the context of the major histocompatibility  complex class II molecule, 
I-A  u, and predominantly use the TCR VB14 gene segment.  This is the first demonstration of 
the physiological  induction of TCR  peptide-specific  CD4 §  T  cells that  result  from MBP 
immunization and that are revealed only during the recovery from disease. The downregulation 
of disease-causing T cells by TCR peptide-specific T cells offers a mechanism for antigen-specific, 
network-induced recovery from autoimmune disease. 
E 
xperimental allergic  encephalomyelitis  (EAE)  t  is  a  T 
cell-mediated autoimmune demyelinating  disease of the 
central nervous system that can be induced after immuniza- 
tion with myelin basic protein (MBP) or its peptide frag- 
ments. TCRs of MBP-reactive T  cells in several strains of 
mice (1-3) and rats (4) have been shown to be encoded by 
a limited set of V region gene segments. After immuniza- 
tion with MBP, most CD4 + T cells in B10.PL or PL/J mice 
recognize the  immunodominant NH2-terminal  fragment 
Acl-9 and a majority of CD4 + T cells use the TCR V138.2 
gene segment (2, 3). The limited use of TCR V genes in 
response to MBP has allowed the use of mAbs to VB8 in 
vivo to successfully prevent EAE (2,  3). 
It has been shown that vaccination with disease-causing 
MBP-reactive CD4 + T cells protects rats from EAE (5, 6). 
This treatment is thought to depend on regulatory responses 
raised to the V region of the TCR.  More recently, it has 
been shown that rats immunized with TCR peptides from 
the CDR II region (amino acids [aa] 39-59)  of the TCR 
/3 or the CDR III region of the TCR oe chain of encephalito- 
1 Abbreviations used in this paper: EAE, experimental allergic encephalomye- 
litis;  MBP, myelin basic protein,  Frx,  pertussis toxin. 
genic T cells are protected from the disease (7-9). However, 
it remains to be established whether the protection from EAE 
by the TCR peptide can be mediated by regulatory T cells 
that are physiologically  induced after MBP immunization (10). 
On the other hand, it has been noted that TCR peptide im- 
munization may lead to the exacerbation of EAE in rats (11). 
The characterization of TCK peptide-reactive  T cells at the 
clonal level and their physiological role during the course of 
EAE has not been clearly established. Moreover, the involve- 
ment of anti-TCR responses in the murine model of EAE 
has not been shown. 
We have studied the dynamics of the spontaneous physio- 
logical induction of anti-TCR peptide responses during EAE 
in B10.PL mice. Antigen-induced disease in B10.PL mice is 
acute but transitory, in that a majority of mice recover per- 
manently from EAE. We reasoned that if TCR peptide-specific 
responses were involved in the regulation of MBP-reactive 
effector T  cells, TCR-reactive T  cells might well become 
primed during recovery from MBP-induced  EAE without 
the necessity for external challenge by TCK peptides. In fact, 
we demonstrate here that the peripheral T cells from mice 
recovered from MBP-induced EAE proliferate to the domi- 
nant TCR peptide B5 (aa 76-101) from framework region 
III of the V/38.2 chain.  We have isolated V/314-expressing 
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CD8-,  and are MHC class II restricted. In adoptive transfer 
experiments, the B5-reactive T  cell clones specifically inhibit 
proliferative responses to Acl-9 and protect mice from MBP- 
induced  EAE.  Thus,  our  study  clearly  demonstrates  the 
antigen-dependent, in vivo priming of regulatory T cells with 
specificity for a dominant TCR peptide determinant in animals 
recovering from EAE. 
Materials and Methods 
Mice.  B10.PL mice were purchased from The Jackson Labora- 
tory (Bar Harbor, ME) and bred under specific pathogen-flee con- 
ditions in our own colony. Female mice were used at 8-14 wk of age. 
Antibodies.  For staining TCR peptide-specific T cells, the fol- 
lowing mAbs were used: anti-CD4-PE and anti-CD8-FITC (GK1.5 
and 53-6, respectively, from Becton Dickinson & Co., Mountain 
View, CA), anti-VB14 (14-2, rat IgM; 12), and anti-V/~3 (KJ-25; 
13). All of the other tested anti-TCR-V/3-specific antibodies,  anti- 
TCR VBs 2 (B20.6), 5 (MR9-4), 6 (RR4-7), 7 (TR310), 9 (MR10- 
2), 10 (B21.5), 11 (RR3-15), 13 (MR12-3),  and V/317 (KJ-23), were 
from Pharmingen (San Diego, CA).  MHC restriction of TCR- 
specific T  ceUs was determined using anti-I-A  u (10-2-16), anti-I- 
E  u (14.4.4S),  anti-CD4  (GK1.5),  and  anti-CD8  (53.6.72)  anti- 
bodies. Purified anti-CD3 (145.2Cll) (14) and anti-V/~8.2 (F23.2) 
(15) antibodies were used for TCR crosslinking experiments. The 
hybridomas producing anti-VB8.2  and anti-VB14 antibodies were 
generously provided by Drs. Michael Bevan (University of Wash- 
ington, Seattle, WA) and David Raulet (University of California, 
Berkeley, CA), respectively. 
TCR Peptides.  TCR peptides were synthesized by S. Horvath 
(Caltech, Pasadena, CA) using a solid phase technique on a peptide 
synthesizer (430A; Applied Biosystems, Inc., Foster City, CA) and 
were purified on a reversed phase column by HPLC (16). TCR VB8.2 
chain peptides correspond to the sequence predominantly used in 
the MBP-specific response in B10.PL mice (2) and are as follows 
(single-letter amino acid code): B1, EAAVTQSPKNKVAVTGGK- 
VTLSCNQTNNHNL (1-30,L); B2, LSCNQTNNHNNMYWY- 
RQDTGHGLRLIHYSY  (21-50);  B3,  HGLRLIHYSYGAGST- 
EKGDIPDGYKASRPS (41-70); B4, PDGYKASRPSQENFSLIL- 
ELATPSQTSVYF (61-90); B5, LILELATPSQTSVYFCASGDA- 
GGGYE (76-101). 
Lymph Node and Splenic Proliferation Assay.  Lymph nodes or 
spleens of mice were removed 10 or 30 d after immunization and 
a single cell suspension  was prepared.  Lymph node cells (4  x  105 
cells per well) and splenocytes  (8  ￿  10  s cells per well) were cul- 
tured in 96-well microtiter plates in 200/zl of serum-free medium 
(HL1; Ventrex, Portland, ME) supplemented with 2 mM gluta- 
mine; peptides were added at concentrations ranging from 0.1 to 
7/xM final concentration. Proliferation was assayed by addition of 
1 #Ci [3H]thymidine (International Chemical and Nudear, Irvine, 
CA) for the last 18 h of a 5-d culture, and incorporation of label 
was  measured by liquid scintillation counting. 
Antibody-dependent Proliferation.  96-well plates were coated with 
50/~1 of a solution of goat anti-hamster or goat anti-mouse anti- 
body (10/~g/ml;  Southern Biotechnology Assodates, Birmingham, 
AL) in PBS at 37~  for 1 h. After washing the wells two to three 
times  with  PBS,  various  concentrations  of purified  anti-CD3 
(145.2.Cll;  14) or anti-V~8.2  (F23.2;  15) antibodies were added 
to the wells in a total volume of 50/zl. Plates were incubated at 
37~  for 90 rain and washed twice with PBS. Lymph node T cells 
(2  x  10  s) were added  to wells  in  a final volume of 200/xl of 
serum-free  medium  (HL-1)  in  triplicate.  2  d  later,  1  /~Ci of 
[3H]thymidine  was added to each well. Plates were harvested  18 h 
later and proliferation was determined by scintillation counting. 
Establishment oft Cell Lines and Clones.  TCR peptide-specific 
T cell lines were established  from B10.PL mice after peptide im- 
munization as well as from mice that had recovered from EAE. 
Mice were immunized in the hind foot pads with 7 nmol of pep- 
tide in saline, in a 1:1 emulsion with CFA. After 10 d, the draining 
lymph nodes were removed and single cell suspensions  were cul- 
tured at a concentration of 4  x  10  s cells/ml in serum-free HL-1 
medium.  After  7-10  d  of culture,  the  cells  were washed  and 
resuspended with antigen (0.3/~M) and syngeneic irradiated spleen 
cells in DMEM (supplemented with 1 mM glutamine, 1 mM pyru- 
vate, 0.05 mM 2-ME, and 10% FCS).  They were maintained by 
periodic restimulation with TCR peptides every 10-15 d. T  cell 
lines, selected from mice recovered from EAE, were only reactive 
to TCR peptide BS. 
T cell clones were isolated from TCR peptide-specific lines by 
the technique of two sequential limiting dilution clonings at 0.2 
cells per well (17). The antigenic specificity of T cell clones was 
confirmed by incubating 0.5-1  x  105 cells per well with irradi- 
ated syngeneic spleen cells (APC) at 1-5  x  10  s cells per well in 
the absence or presence of TCR peptides at different concentra- 
tions (1 nM to 14 #M). Proliferation of T cell clones was measured 
by [3H]thymidine incorporation for the last 18 h of a 3-d culture 
as described above. 
Adoptive Transfer  Exlx"riments with T Cell Clones Specific  for B5.  In 
adoptive transfer experiments, TCR peptide-specific T cells (B5.2 
and B4.1) were activated for 3 d with peptide B5 and B4, respec- 
tively, in the presence of syngeneic spleen cells. At the end of the 
culture, cells were passed through Ficoll-Hypaque and the live cells 
washed thoroughly three times with saline, counted, and injected. 
10 d later,  lymph node proliferative recall responses  were deter- 
mined as described in the lymph node and splenic proliferation assay 
section. 
Induction of  EAE.  MBP was isolated from the brains of guinea 
pigs (pal-Freez Biologicals, Rogers, AR) as described (18). For in- 
duction of EAE, mice were immunized subcutaneously with 100 
#g gpMBP in CFA and 0.1/~g pertussis toxin (PTX; List Biolog- 
ical, Campbell, CA) was injected in 200 #1 saline intravenously 
24 and 72 h later. Mice were observed daily for signs of EAE and 
until >'60 d after MBP immunization. The average disease score 
for each group was calculated by averaging the maximum severity 
of all of the affected animals  in the group. Also,  the maximum 
disease score of each animal is given in parentheses. Disease severity 
was scored on a five-point scale (19): 1, flaccid tail; 2, hind limb 
weakness; 3, hind limb paralysis; 4, whole body paralysis; 5, death. 
Onset of disease is defined as the first signs of loss of tail tone or 
hind limb weakness,  averaged over the affected group. 
Flow Cytometry Analysis.  Antibodies were purified from hy- 
bridoma supernatants by protein A chromatography. Anti-VB14 
antibody was biotinylated with NHS-LC-biotin (Pierce, Rockford, 
IL) according to the manufacturer's recommendations. Antibodies 
were used in PBS containing 1% FCS. 106 cells were stained with 
0.5 #g of antibody in a total volume of 50/~1 at 4~  for 30 rain. 
Cells were washed twice with PBS and then resuspended in a 50 
/~1 of a 1:50 dilution of either FITC-conjugated streptavidin or goat 
anti-mouse  Ig-FITC  (Southern  Biotechnology Associates,  Bir- 
mingham, AL). After 20 rain at 4~  cells were washed, fixed with 
1% paraformaldehyde in PBS, and analyzed using a cytofluorograph 
(Becton Dickinson & Co.). 
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Peripheral T Cells  from Mice Recovering  from EAE Proliferate 
Only to the Imraunodominant TCR Peptide B5.  To test the 
possibility that TCR peptide-specific T  cells are naturally  ~, 
primed during recovery from EAE, we synthesized 25-30  o 
residue-long peptides with 10-15 amino acid overlaps from  x 
both TCR chains (V/58.2 and Vc~2.3) of a representative T  Z  a. 
cell clone predominant in the MBP-specific response in B10.PL  o 
mice (2) (see/5 chain peptides in Materials  and Methods). 
The specific proliferative responses to the 10 TCR peptides 
were followed in splenic T cells 30 d after immunization with 
MBP/CFA and PTX, well past the start of recovery from EAE. 
A proliferative response to a single TCR peptide, B5 (aa 
76-101),  was revealed in the peripheral T  cells (Fig.  1 B). 
Notably, only B5-specific T cells are primed, although TCR 
peptides B2 (aa 21-50)  and B4 (aa 61-90) from the TCR/5 
chain and A4 and A5 from the TCR c~ chain were also capable 
of inducing vigorous T cell proliferation when injected into 
B10.PL mice as peptides (V. Kumar, R. Tabibiazar, H. M. 
Geysen, and E. Sercarz,  manuscript in preparation). Thus,  o 
during the course of recovery from MBP-induced EAE, T 
cells reactive to a single TCR determinant (within B5) from  a.s* 
o  the V/58.2 chain are generated in vivo, despite the presence 
of several other potential T cell determinants on the TCR. 
Thus, B5 can be considered physiologically dominant while 
determinants in B2 and B4 appear cryptic. Importantly, B5- 
reactive T cells were not detected among spleen cells from 
MBP/CFA/PTX-immunized mice before the onset of EAE 
(Fig.  1 A) or from unimmunized animals (Fig.  1 C). 
B5-reactive T Cell Clones Express CD4 and Are MHC Class 
II Restricted.  To further study the characteristics of the B5- 
specific T cells, we established 2 proliferative  T cell lines, 3 
clones,  and 26 hybridomas specific for this peptide. T  cell 
lines were selected from B10.PL mice that were immunized  ~'  O 
with B5 as well as with MBP/CFA/PTX (see Materials and  x 
Methods). Also, for comparison, T cell clones reactive to B4  5 
(B4.1 and B4.2) were generated after immunization with B4  oa" 
in CFA. These T cells were examined for MHC restriction, 
cell surface expression of CD4, CD8, and TCR, and their 
ability to modulate proliferative  responses to Acl-9 in vivo 
and EAE.  T  ceU clones B5.1  and B5.2 were derived from 
two independent lines and were used to study downregula- 
tion of the MBP-specific response. 
Earlier studies in rats have shown that CDR II region TCR 
peptide-induced bulk T cell lines appear to be restricted by 
class I MHC molecules, although they were positive for both 
CD4 and CD8 markers (7). However, more recently,  CD4- 
enriched splenic cells from recovered rats have been shown 
to recognize the same TCR peptide from the CDR II region 
in a class II context (20).  Staining of cloned B5-specific T 
cells with anti-CD4 and anti-CD8 antibodies revealed that 
B5.2 as well as other BS-reactive T cell clones, hybridomas, 
and lines only express CD4 and not CD8 molecules (Fig. 2). 
Proliferation of T cell clones (B5.1 or B5.2) was blocked 
by anti-I-A  u (10-2-16) as well as by anti-CD4 antibodies (GK 
1.5), but not by anti-I-E  u (14.4.4S) or anti-CD8 antibodies 
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Figure  1.  T cells reactive to the immunodominant TCR peptide B5 
become primed in mice recovering  from EAE. B10.PL mice were immunized 
with MBP/CFA and PTX (48 and 72 h later). 10 d (-4) and 30 d (B) later, 
the proliferative recall responses to the immunogenic  TCR peptides from 
the VB8.2 chain were tested in the spleen. Proliferation to the TCR pep- 
tides was also tested in spleen cells from unimmunized mice (C).  Mice 
in the 30-d group had recovered from whole body and hind limb paralysis 
by the time of the assay. Responses to TCR peptides: none ([-1), B2 ([]), 
B4 ([]), and B5 (m), at an optimum concentration (3/zM) in individual 
mice, are shown.  The data are expressed as arithmetic means  _+  SD of 
[3H]thymidine incorporation (cpm  xl0 -3) in triplicate cultures. This ex- 
periment is one representative of four separate experiments. 
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Figure 2.  BS-reactive  T cells 
are CD4 §  , CD8-, and predom- 
inantly use the TCR VB14 gene 
segment. T cell clone 5.2 was 
stained  with various  mAbs  and the 
fluorescence  was measured  by flow 
cytometry  analysis;  representative 
histograms are shown. (A) Goat 
anti-mouse Ig-FITC only; (B) 
anti-CD4-PE (GK1.5); (C) anti- 
CD8 (53-6) and goat anti-mouse 
Ig-FITC; (D) streptavidin-FITC 
only; (E) biotinylated  anti-V/~14 
(14-2) and streptavidin-FITC. 
TCR peptide B5 to specific T cell hybridomas was examined 
using L cell transfectants expressing MHC class II molecules. 
B5-reactive  T  cell hybridomas were stimulated by B5 only 
in the presence  of L cell transfectants expressing I-A  u, and 
not by L ceils expressing I-A  d (data not shown). 
B5.specific T Cells Predominantly Use the TCR  Vf114 Gene 
Segment.  How heterogeneous is the population of regula- 
tory CD4 + T cells? We have tested VB gene segment usage 
in these cells by staining with various available anti-TCR VB 
chain antibodies. Interestingly, B5-specific T cells predomi- 
nantly use the VB14 gene segment, in that 26 (3 clones and 
23  hybridomas) of 29  cloned T  cells generated from two 
different animals stained positively with the anti-VB14 anti- 
body (biotinylated-14-2 [12]) and no other biotinylated anti- 
body (Fig. 2). Each of the three T cell hybridomas negative 
for V~14  used  the V~3  gene segment (R-PE-conjugated 
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Figure  3.  TCR peptide-reactive  regulatory  T cells  are restricted  by the 
class II MHC molecule;  B5-specific  proliferation  of  done B5.2 is inhibited 
in the presence of anti-l-A~ antibodies. [3H]Thymidine  incorporation  in 
response to an optimum  concentration  of TCR peptide  B5 (0.7/zM) and 
irradiated syngeneic  spleen cells was measured  in the presence of an op- 
timum  concentration  of  various  antibodies:  anti-I-A, anti-/-E, anti-CD4, 
and anti-CD8. 
TCR Peptide-spedfic CD4 + T Cell Clones Specifically Down- 
regulate Proliferative Responses to Acl-9.  Immunization with 
TCR peptide B5, but not B2 or B4, was able to specifically 
downregulate Acl-9 responses  in B10.PL  mice (V. Kumar, 
R.  Tabibiazar,  H.  M.  Geysen,  and E.  Sercarz,  manuscript 
in preparation). It was important to test whether the regula- 
tory activity could be adoptively transferred with CD4 + T 
cells that are able to proliferate to B5. T cell clone B5.2 was 
transferred intraperitoneally, and on the same day or a day 
later, mice were injected with MBP/CFA subcutaneously. After 
10 d, lymph node or splenic responses were recalled in vitro 
with Acl-9 (Fig. 4 A), gpMBP (Fig. 4 B), or gpMBP 43-57 
(Fig. 4 C). Clearly, administration of B5-reactive T cell dones, 
but not B4-specific T cells, was able to downregulate prolifer- 
ative responses to Acl-9. Similar data were obtained with an- 
other B5-specific clone, B5.1,  as well as with T  cell lines. 
However, there was no effect on proliferative recall either to 
the unique xenogeneic determinants on gpMBP (Fig.  4 B) 
or to a single xenogeneic determinant, gpMBP 43-57  (Fig. 
4 C), to which the B10.PL mouse has an equivalent response 
to  that  of Acl-9.  Furthermore,  recall  responses  either  to 
gpMBP or to 43-57 of gpMBP were not inhibited even when 
titrated to lower concentrations (0.1/xM). Responses against 
xenogeneic determinants served as internal controls for any 
912  TCR Pepride-specific Regulatory  T Cells in Autoimmune  Disease 20 
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Figure  4.  TCR peptide-reactive  T cell clone B5.2 specifically downregulates  proliferative responses to Acl-9 in B10.PL mice. Groups of mice were 
immunized intraperitoneally  with the activated B5.2 T  cell clone (four animals,  5  ￿  10  s cells;  five animals,  1  ￿  10  s cells),  B4.1  T  cells  (5  ￿  10  s 
cells),  in 0.5 ml saline and saline only (Control).  The next day all the animals were immunized subcutaneously  with 100/~g guinea pig MBP in CFA. 
9-10 d later, lymph node proliferative responses to Acl-9 (A) or to the xenogeneic determinants  on MBP (B) or to a single xenogeneic determinant 
of gpMBP, p43-57 (C),  were measured at an optimum concentration  of antigen (7/~M).  Background  incorporation  with medium alone ranged from 
754 to 2,178 cpm. The data are expressed as arithmetic  means of [3H]thymidine incorporation  (cpm  ￿  10-3) in triplicate cultures. These data are repre- 
sentative  of three separate experiments. 
generalized,  nonspecific effect on proliferation and dearly argue 
against ergotypic regulation  (21) in this model.  It is note- 
worthy that the downregulation was ef~cient after transfer 
of as few  as  10  s B5-specific  T  cells. 
Regulatory  T  Cells Do Not Anergize All V~8.2 + T  Cells. 
We have asked whether the B5-reactive T cells induce inacti- 
vation  of all  T  cells  expressing  the V~8.2  receptor.  Since 
B10.PL T cell proliferative responses that predominantly use 
the V/~8.2 gene segment other than to Acl-9 are not known, 
using mAbs to V/~8.2 as well as to CD3,  we have studied 
proliferation induced by receptor crosslinking. Clearly, lymph 
node T cells from mice transferred with B5.2 clones prolifer- 
ated to a similar extent in comparison to lymphocytes from 
mice receiving saline only (Fig.  5).  In four separate experi- 
ments, although the incorporation varied, there was no change 
in the profile. This suggests that B5-reactive T  cells did not 
anergize or inactivate a majority of V/~8.2 + T  cell popula- 
tion. This is in contrast to the result with a CDR II region 
VB8  peptide  that  induced  clonal  unresponsiveness  in  all 
VB8.2 +  T  cells  in DBA  2  or (PL/J  x  SJL)F1 mice (23). 
B5-specific CD4 +  T  Cell Clones Protect Mice from  MBP- 
induced EAE.  To determine  the physiological  significance 
of regulatory T cell clones in modulation of EAE, after transfer 
of 10  s B5.2 cells,  mice were tested to see if they were pro- 
tected from MBP-induced EAE. In two separate experiments, 
a total of 16 mice that had received activated, BS-specific cloned 
T  cells were protected significantly from EAE (Table  1).  In 
contrast, parallel experiments with adoptively transferred B4- 
reactive T cells (B4.1) showed no effect on the course of the 
disease (Table 1). Apparently, the response to the xenogeneic 
determinants  on guinea pig MBP  is of little  or no conse- 
quence for the disease process. 
Discussion 
EAE serves as a prototype for T cell-mediated autoimmune 
diseases.  Although a great deal is known about the induc- 
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Figure  5.  B5 peptide-specific  T cells do not induce generalized clonal 
unresponsiveness in V/~8.2 + T cells. TCR antibody-induced  proliferation 
of lymph node T cells from B10.PL mice were transferred with clone B5.2 
in saline (g~) or saline only (m), as in the legend for Fig. 4. TCR cross- 
linking experiment using plate-bound anti-VB8.2 or anti-CD3  (see Materials 
and Methods)  was performed on the same day as proliferation to Acl-9. 
The data from groups of two mice each are expressed as arithmetic means 
of [3H]thymidine incorporation  (cpm  x 10-3) in triplicate cultures. These 
data are representative of four  separate experiments. 
913  Kumar and Sercarz Table  1.  Regulatory T  Cell Clones Protect Mice from MBP-induced EAE 
Exp.  Treatment* 
Mice with  Average score 
EAE/total  (individual 
mice  scores)  Time of onset 
d 
B5.2 T  cells  0/6  N/A  N/A 
B4.1 T  cells  4/6  2.7  (4,3,3,1)  20 
None  4/5  3.0 (5,3,3,1)  20 
B5.2 T  cells  1/10  1.0  21 
B4.1 T  cells  9/10  3.2 (5,5,5,4,3,2,2,2,1)  19 
...................... 
* Age-matched female B10.PL mice were treated intraperitoneally with activated and Ficoll-Hypaque-purified  TCR peptide-specific  T cells (B5.2, 
1-5  x  105 cells; and B4.1, 5  x  105 cells) in 500 #1 saline. 24 h later, EAE was induced with MBP as described in Materials and Methods. 
the physiological mechanisms involved in regulation of MBP- 
reactive T  cells in vivo. This study takes an initial  step to- 
wards analyzing anti-TCR responses in murine EAE and their 
possible role in the regulation of the MBP-specific response. 
We have studied the dynamics of the spontaneous induction 
of an anti-TCR peptide response during MBP-induced EAE. 
We have demonstrated the antigen-dependent, in vivo priming 
of anti-TCR regulatory T  cells in B10.PL mice recovering 
from EAE.  We have shown that  downregulation  by these 
CD4 § T  cells is determinant  specific. The physiological rel- 
evance of these findings was confirmed by adoptive transfer 
experiments,  where cloned T  cells prevented MBP-induced 
autoimmunity. 
The regulatory T ceils reactive to the TCR-peptide B5 (aa 
76-101)  are primed  naturally  during  the  course  of MBP- 
induced disease, despite the presence of many other potential 
T  cell determinants  on both the TCR c~ and ~  chains.  Im- 
portantly, only T cells reactive to the immunodominant pep- 
tide (B5) are capable of modulating anti-MBP responses while 
T cells specific for other TCR peptides, for example, B4 (61-90) 
or B2 (21-50), are not. It may be that B2 and B4 are cryptic 
determinants in that they can induce T  cells upon immuni- 
zation as peptides but fail to do so naturally in the context 
of the whole TCR molecule and therefore are not part  of 
the regulatory network. Recently, it has been reported that 
CDR II peptide 39-59 from the TCR V/~8.2 chain may be 
a cryptic determinant because it failed to elicit regulatory T 
cells  in  Lewis rats  (10).  In  B10.PL or  (B10.PL  x  SJL)F1 
mice, the TCR Vf18.2 peptide (B3, aa 41-70) almost encom- 
passing the entire CDR II region (aa 39-59) did not elicit 
a proliferative  response  (V.  Kumar,  R.  Tabibiazar,  H.  M. 
Geysen, and E. Sercarz,  manuscript in preparation), although 
such a response has recently been shown in (PL/J  x  SJL)F1 
mice (22). Background genes between B10.PL and PL/J mice 
may be responsible for such differences.  Therefore, CDR II 
region peptides from the TCR V~ chains may not induce 
regulation  in all  strains  of mice and rats. 
Fine specificity mapping  of the minimal  determinant  in 
B5 (aa 76-101) indicated that amino acid residues PSQTSV- 
YFCA (aa 83-92) constitute a core essential for recognition 
by the regulatory T  cells (V. Kumar,  R. Tabibiazar,  H. M. 
Geysen, and E.  Sercarz,  manuscript  in preparation).  These 
residues are near the COOH terminus  of the VBS.2 chain 
in the putative V3 framework region III (23) not including 
the D-J (CDR III) region. Interestingly, it has been suggested 
that residues in framework region III are relatively superficial 
and accessible;  for example, they are involved in binding to 
superantigens (24). Also, autoantibodies from individuals  with 
certain autoimmune diseases have been shown to bind to this 
antigen.  (25). 
B5-reactive T cells are of limited heterogeneity in that they 
predominantly use a single TCR VB gene segment, VB14. 
This limited diversity of TCR peptide-reactive T  cells may 
be simply owing to their restricted specificity.  It may also 
reflect that these T cells themselves are a highly focused target 
for regulation  (26,  27). 
This study demonstrates that the regulation of the MBP- 
specific response by TCR peptide BS-reactive CD4 + T cells 
only affects T cells using the TCR V38.2 gene segment, but 
does not affect all such T  cells. Clearly, the proliferative re- 
sponse  to  Acl-9  was inhibited  while  responses  to  unique 
xenogeneic determinants  on guinea pig MBP,  presumably 
using other TCR V3 gene segments, were not affected. Like- 
wise, VB14 + regulatory T cells do not appear to downregu- 
late all V38.2 § T  cells but rather  those specific for Acl-9. 
In contrast  to a recent report  that  TCR peptide (CDR II 
region) immunization  in DBA/2 or (PL  x  SJL)F1 mice in- 
hibited the V38.2-restricted response to peptide 110-121  of 
sperm whale myoglobin and led to clonal unresponsiveness 
in all V38.2 § T  cells (22),  adoptive transfer of B5-reactive 
T  cells did not result in generalized anergy.  These findings 
argue against  generalized  suppression or ergotypic regula- 
tion,  which  has been proposed in other  systems (21). 
The physiological induction of B5-reactive T cells during 
the recovery from MBP-induced EAE, and the fact that cloned 
CD4 ~ , V~14 + T  cells are capable of protecting mice from 
the disease even when transferred at a low number,  suggest 
their  involvement  in  regulating  the  response  to  the  im- 
914  TCR Peptide-specific Regulatory T Cells in Autoimmune Disease munodominant Acl-9. Thus, natural priming and very effec- 
tive protection from EAE suggest that B5-specific T cells are 
involved in a TCR-based regulatory network responsible for 
the transient nature of the disease.  Other investigators have 
found that  a polyclonal,  nylon wool-adherent,  CD4+-en - 
riched splenic suppressor population (10  s cells), from post- 
recovery rats,  did not protect  animals  from EAE unless B 
cells  from immunized  rats were also transferred  (20). 
Mouse T cells do not generally express class II MHC mol- 
ecules and therefore may not be able to present self-TCR pep- 
tides  (28,  29).  How  then  do  the  TCR  peptide-reactive 
CD4 § T  cells become primed in vivo? We favor the view 
that professional APC, for example, TCR-specific B cells or 
macrophages, could pick up the TCR or TCR-Ab complex 
at the inflammatory  sites and present TCR peptides to the 
regulatory  CD4 § T  cells  in the context  of MHC class  II. 
We have found that if a higher number (2-5  x  106/200 #1) 
of splenic APCs is used, the B5.2 T cell clone can be stimu- 
lated without  the addition  of exogenous TCR peptide B5 
(unpublished observation). We are currently attempting  to 
define the molecular form  of the B5 peptide that  is taken 
up by the splenic APCs.  It should however be emphasized 
here that whatever the mechanism of processing and presen- 
tation of TCR peptides, BS-reactive T  cells become primed 
in  vivo in  the  absence of any external  challenge  with  the 
peptide. 
How do regulatory CD4 § T  cells actually downregulate 
the V~88.2 + effector T  cells?  There are at least two possi- 
bilities:  first,  regulatory  T  cells  could  secrete modulating 
cytokines, e.g., TGF-/3 (30) or IL-10 (31), acting locally and 
directly on targets at the site of inflammation.  Second, B5- 
reactive T  cells could recruit CD8 + T  cells that  specifically 
recognize peptides from either  the native tx or/5 chain  of 
the TCR in the context of MHC class  I  at  the surface of 
MBP-reactive effector T cells (32).  The display of TCR pep- 
tide-class  I  complexes on  activated Acl-9-specific VB8.2 + 
effector T cells may provide the basis for specific recognition 
and  downregulation  by  CD8 +  T  cells.  Recently,  CD8 
knock-out or antibody-mediated depletion have demonstrated 
discrete effects but have not indicated an obligatory role for 
CD8 + T  cells in the recovery from EAE  (33, 34).  In pre- 
liminary experiments, we have found that the adoptive transfer 
of B5.2 T cells did not effectively downregulate the prolifer- 
ative response to Acl-9 in the recipients when CD8 + T cells 
were deleted in vivo after anti-CD8 mAb treatment. Demon- 
stration of this requirement for CD8 + T cells in our system 
is consistent with a recent report of Gaur et al.  (22),  who 
showed requirement  of CD8 + T  cells in TCR peptide-in- 
duced clonal unresponsiveness. 
We have found that B5-specific regulatory cells are not re- 
vealed before the onset of disease in mice that received MBP 
and PTX injections.  Also, we were unable to detect a prolifer- 
ative response in vitro to the TCR peptide B5 in splenic cells 
from naive B10.PL mice. There are at least two possibilities 
to explain these findings.  First, regulatory T cells may only 
become reactivated or primed after many effector T cells have 
been expanded during EAE. Second, these cells may be nor- 
mally activated and constitute an integral part  of a regula- 
tory homeostatic mechanism maintaining tolerance to MBP, 
and initially may be inhibited  in some way (maybe in  the 
presence of strong  adjuvants). 
What is evident from our results is that during the course 
of activation of the disease-inducing arm of the immune re- 
sponse to autoantigen,  networks for its downregulation are 
engaged. Such antigen-initiated  regulation that works through 
recognition of dominant TCR determinants suggests the pres- 
ence of preexisting idiotypic mechanisms  (26).  It has been 
suggested that certain dominant idiotypic motifs are favored 
in the regulatory network presumably because they can pro- 
vide a necessary focus for regulation (26, 27). Thus, a TCR- 
based network may be responsible for the transient and self- 
limiting  nature  of autoimmune  encounters. 
We thank Drs. Raft Ahmed, Vatsala Bhardwaj, Mitch Kronenberg, Paul Lehmann, and Alexander Miller 
for critical suggestions; S. Horvath and Craig Miles for synthesizing peptides; and Raymond Tabibiazar 
and Richard  Trezza for technical assistance. 
This work was supported by grants  AI-28419 and AI-11183 from the National  Institutes  of Health,  as 
well as RG-1755 from the National  Multiple  Sclerosis Society. 
Address  correspondence to Vipin Kumar or Eli Sercarz, Department of Microbiology and Molecular Genetics, 
College of Letters and Science, 5304 Life Sciences Building or Molecular Sciences Building, Los Angeles, 
CA 90024. 
Received.for publication 24 May 1993. 
References 
1.  Kumar, V., D. Kono, J. Urban,  and L. Hood. 1988. T cell 
receptor repertoire and autoimmune  diseases. Annu. Rev. lm- 
munol. 7:657. 
2.  Urban, J.L., V. Kumar, D.H. Kono, C. Gomez, S.J. Horvath, 
J. Clayton, D.G. Ando, E.E. Sercarz, and L. Hood. 1988. Re- 
stricted use of T cell receptor V genes in murine autoimmune 
915  Kumar  and Sercarz encephalomyelitis raises possibilities for antibody therapy. Cell. 
54:577. 
3.  Acha-Orbea, H., D.J. Mitchell, L. Timmermann, D. Wraith, 
G.S. Tausch, M.K. Waldor, S.S. Zamvil, H.O. McDevitt, and 
L. Steinman. 1988. Limited heterogeneity of T cell receptors 
from lymphocyte mediating autoimmune encephalomyelitis 
allows  specific immune intervention. Cell. 54:263. 
4.  Heber-Katz, E., and H. Acha-Orbea. 1989. The V-region hy- 
pothesis:  evidence  from autoimmune encephalomyelitis.  Im- 
munol. Today. 10:164. 
5.  Ben-Nun, A., H. Wekerle,  and I.R. Cohen.  1981. Vaccina- 
tion against  autoimmune encephalomyelitis using attenuated 
cells of a T lymphocyte line reactive against  myelin basic pro- 
tein. Nature (Lond.). 292:60. 
6.  Lider, O., T. Reshef, E. Beraud, A. Ben-Nun, and I.R. Cohen. 
1988. Anti-idiotypic network induced by T  cell vaccination 
against  experimental autoimmune encephalomyelitis.  Science 
(Wash. DC).  239:181. 
7.  Vandenbark,  A.A., G. Hashim, and H. Offner. 1989. Immu- 
nization with a synthetic T-cell receptor V-region peptide pro- 
tects against experimental autoimmune encephalomyelitis. Na- 
lure (Lond.). 341:541. 
8.  Howell, M.D., S.T. Winters, T. Olee, H.C. Powell, D.J. Carlo, 
and S.W. Brostoff. 1989. Vaccination against  experimental al- 
lergic encephalomyelitis  with T cell receptor peptides. Science 
(Wash. DC).  246:668. 
9.  Offner, H.,  G.  Hashim,  and  A.  Vandenbark.  1991. T  cell 
receptor peptide therapy triggers autoregulation  of experimental 
encephalomyelitis.  Science (Wash. DC).  251:430. 
10.  Sun, D.  1992. Synthetic peptides representing sequences  39 
to 59 of rat V/38 TCR fail to elicit regulatory T cells reactive 
with V/38 TCR on rat encephalitogenic T cells. Cell. Immunol. 
141:200. 
11.  Desquenne-Clark,  L., T.R. Esch, L. Otvos, and E. Heber-Katz. 
1991. Studies of V/38 T cell receptor peptide treatment in ex- 
perimental autoimmune encephalomyelitis. Proc Natl. Acad. Sci. 
USA.  88:7719. 
12.  Liao, N.-S., J. Maltzman, and D.H. Raulet. 1989. Positive se- 
lection determines T cell receptor V/314 gene usage by CD8 + 
T  cells. J. Exp. ivied. 170:135. 
13.  Pullen, A., P. Marrack, and J.W.  Kappler.  1988. The T  cell 
repertoire is heavily influenced by tolerance to polymorphic 
self antigens. Nature (Lond.). 355:796. 
14.  Leo, O., M. Foo, D.H. Sachs, L.E. Samelson,  and J.A. Blue- 
stone. 1987. Identification of a monoclonal antibody specific 
for a  murine  T3  polypeptide. Proc. Natl.  Acad. Sci. USA. 
84:1374. 
15.  Kappler, J.W., U. Staerz, J. White, and PC. Marrack.  1988. 
Self tolerance eliminates T cells specific for Mls-modified prod- 
ucts of the major histocompatibility complex. Nature (Lond.). 
332:35. 
16.  Clark-Lewis, I., R. Aebersold, H. Ziltener, J.W. Schrader, L.E. 
Hood, and S.B.H. Kent. 1986. Automatic chemical synthesis 
of a protein growth factor for hemopoietic cells, interleukin-3. 
Science (Wash. DC).  231:134. 
17.  Kimoto, M., and C.G. Fathman. 1980. Antigen-reactive T cell 
clones I. Trans-complementing hybrid I-A-region  gene prod- 
ucts function effectively in antigen presentation. J. Exp. Med. 
152:759. 
18.  Smith, M.E. 1969. An in vitro system for the study of myelin 
synthesis. J. Neurochem. 16:83. 
19.  Zamvil, S., P. Nelson, J. Trotter, D. Mitchell, R. Knobler, R. 
Fritz, and L. Steinman. 1985. T cell clones specific for myelin 
basic protein induce chronic relapsing paralysis and demyelina- 
tion. Nature (Lond.). 317:355. 
20.  Karpus, W.J., K.E. Gould, and R.H. Swanborg.  1992. CD4 + 
suppressor  cells of autoimmune encephalomyelitis respond to 
T  cell  receptor-associated  determinants  on effector cells by 
interleukin-4 secretion. Eur. J. Immunol.  22:1757. 
21.  Lohse, A.W., F. Mot, N. Karin, and I.R.. Cohen. 1989. Con- 
trol of experimental autoimmune encephalomyelitis by T cells 
responding to activated T cells. Science (Wash. DC).  244:820. 
22.  Gaur, A.,  R. Haspel, J.P. Mayer, and C.G. Fathman.  1993. 
Requirement  for  CD8 §  cells  in  T  cell  receptor  peptide- 
induced clonal unresponsiveness.  Science (Wash. DC).  259:91. 
23.  Chothia, C., D.R.. Boswell,  and A.M. Lesk.  1988. The out- 
line structure of the T cell ct/3 receptor. EMBO (Eur. Mol. Biol. 
Organ.) J.  3745-3755. 
24.  Pullen, A.N., T. Wade, P. Marrack, and J.W. Kappler.  1990. 
Identification of the region of T cell receptor/3 chain that in- 
teracts with the self-superantigen  Mls-1 ~. Cell. 61:1365. 
25.  Marchalonis, J.J., H. Kaymaj, F. Dedeoglu, S.F. Schluter, D.E. 
Yokum, and A.B. Edmundson.  1992. Human autoantibodies 
reactive  with synthetic autoantigens from T-cell receptor/3 
chain. Proc. Natl.  Acad. Sci. USA.  89:3325. 
26.  Cohen, I.R.., and D.B. Young. 1991. Autoimmunity, microbial 
immunity and the immunological homunculus, lmraunol. Today. 
12:105. 
27.  Kumar, V., and E. Sercarz.  1992. T cell regulatory circuitry: 
antigen-specific  and TCR.-idiopeptide-specific  T  cell interac- 
tions in EAE. Int. Rev. Immunol.  9:269. 
28.  Lorber,  M.L., Ik. Locken, A.M. Stall, and F.W. Fitch. 1982. 
I-A antigen on cloned alloreactive murine T lymphocytes are 
acquired passively. J. Iramunol. 128:2798. 
29.  Benoist,  C.,  and  D.  Mathis.  1990.  Regulation  of major 
histocompatibility class-II  genes:  X, Y, and other letters of 
the alphabet. Annu.  Rev. Immunol.  8:681. 
30.  packe, M.K., S. Dhib-Jalbut, B. Cannella, P.S. Albert, C.S. 
Paine, and D.E. McFarlin. Prevention and treatment of chronic 
relapsing  experimental  allergic  encephalomyelitis by  trans- 
forming growth factor-/31. 1991. J. Immunol.  146:3012. 
31.  Kennedy, M.K., D.S. Torrance, K.S. Picha, and K.M. Mohler. 
1992. Analysis of mRNA expression in the central nervous 
system of mice with experimental autoimmune encephalomy- 
elitis  reveals  that  Ibl0  mRNA  expression  correlates with 
recovery, j.  lmmunol.  249:2496. 
32. Jiang,  H., E. Sercarz,  D. Nitecki, and B. Pernis.  1991. The 
problem of presentation of T  cell receptor peptides by acti- 
vated T  cells. Ann.  NY Acad. Sci. 636:28. 
33.  Koh, D.-R., W.-P. Fung-Leung, A. Ho, D. Gray, H. Acha- 
Orbea, and T.-W. Mak. 1992. Less mortality but more relapses 
in experimental allergic encephalomyelitis  in CD8-/-  mice. 
Science (Wash. DC).  256:1210. 
34. Jiang,  H., S. Zhang, and B. Pernis.  1992.  Role of CD8 + T 
cells in Experimental Allergic Encephalomyelitis. Science (Wash. 
DC).  256:1213. 
916  TCR Peptide-specific Regulatory T Cells in Autoimmune Disease 